Cargando…
Nilotinib treatment-associated accelerated atherosclerosis: when is the risk justified?
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2013
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3768111/ https://www.ncbi.nlm.nih.gov/pubmed/23604230 http://dx.doi.org/10.1038/leu.2013.112 |
| _version_ | 1782283739865284608 |
|---|---|
| author | Tefferi, A |
| author_facet | Tefferi, A |
| author_sort | Tefferi, A |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-3768111 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2013 |
| publisher | Nature Publishing Group |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-37681112013-09-11 Nilotinib treatment-associated accelerated atherosclerosis: when is the risk justified? Tefferi, A Leukemia Letter to the Editor Nature Publishing Group 2013-09 2013-05-17 /pmc/articles/PMC3768111/ /pubmed/23604230 http://dx.doi.org/10.1038/leu.2013.112 Text en Copyright © 2013 Macmillan Publishers Limited http://creativecommons.org/licenses/by-nc-nd/3.0/ This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/ |
| spellingShingle | Letter to the Editor Tefferi, A Nilotinib treatment-associated accelerated atherosclerosis: when is the risk justified? |
| title | Nilotinib treatment-associated accelerated atherosclerosis: when is the risk justified? |
| title_full | Nilotinib treatment-associated accelerated atherosclerosis: when is the risk justified? |
| title_fullStr | Nilotinib treatment-associated accelerated atherosclerosis: when is the risk justified? |
| title_full_unstemmed | Nilotinib treatment-associated accelerated atherosclerosis: when is the risk justified? |
| title_short | Nilotinib treatment-associated accelerated atherosclerosis: when is the risk justified? |
| title_sort | nilotinib treatment-associated accelerated atherosclerosis: when is the risk justified? |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3768111/ https://www.ncbi.nlm.nih.gov/pubmed/23604230 http://dx.doi.org/10.1038/leu.2013.112 |
| work_keys_str_mv | AT tefferia nilotinibtreatmentassociatedacceleratedatherosclerosiswhenistheriskjustified |